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drugs across ATC groups appeared to differ between the EMA and FDA suggesting 
the regulatory bodies may have different preferences with regard to research and 
development in the various therapeutic fields.
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BAckground: In Russia all drugs for state medical organisations and programs 
are purchased through public tenders in order to enhance competition, decrease 
price and prevent corruption. Drugs for rare diseases (DRD) are often produced by 
the only manufacturer thus being monopolistic. There is lack of information about 
the effectiveness of tender procedures for DRD in real life. oBjectives: To assess 
the competition in public procurement of DRD and effectiveness of tender proce-
dures. Methods: The analysis was conducted on the basis of 1499 selected trade 
procedures on DRD procurement in 2013. We evaluated the proportion of procedures 
that have passed with the only one participant, the level of price reduction resulted 
from trading, the amount and volume of purchases of DRD in the subjects of the 
Russian Federation. Data on drug procurement procedures were obtained from the 
official website of state purchases www.zakupki.gov.ru. Data collection and process-
ing were performed using the program Microsoft EXCEL and Statistica 6.1. results: 
Total amount of spending for DRD in 2013 was € 192.23 million, with declared pro-
cedures on € 197.93 million. Competition was absent in 592 (74.47%) procedures of 
monopolistic drugs procurement. 75% of tenders were performed without reduc-
ing the price. There were € 5.69 million savings generated by purchases (3% of the 
amount of declared procedures). conclusions: Tender procedures used for the 
procurement of monopoly drugs are ineffective because of the lack of competition; 
distributors are not interested in price reduction at noncompetitive procedures.
PSY107
comPArAtive AnAlYSiS of the reimburSement lAndScAPe of orPhAn 
druGS on An internAtionAl level
Nazha S
University of Montreal, Montreal, QC, Canada
oBjectives: The objective of this study is to analyze and compare the recom-
mendation made by several countries for orphan drugs such as Canada, Scotland, 
Australia, France and England.The study will try to address solutions and innovative 
ways to evaluate orphan drugs from an economic perspective and try to propose 
the hallmarks of an ideal policy to be implemented. Methods: The Orphanet 
website was screened to find orphan drugs with national designations.237 orphan 
drugs indication were retrieved and 36 technologies were included in the study and 
stratified by therapeutic areas.In total, 180 recommendations were analyzed for the 
5 included HTA agencies. Each recommendation was analyzed for the following 
parameters: Listing, clinical recommendation, economic recommendation, QALYs 
and rarity of disease taken in consideration. results: Scotland (88%) was the coun-
try that took the most in consideration the orphan designation of drugs, followed by 
France (74%) and Australia (45%). In addition, France and Scotland were the 2 coun-
tries that had the most positive listings (with criteria or without). The clinical benefit 
was demonstrated in multiple drugs throughout the different agencies. However, the 
economic part was very heterogeneous. Scotland issued a lot of positive economic 
recommendations (60%); however countries such as Canada had a very low percent-
age of economic being accepted (19%). QALYs did not seem to correlate with the type 
of listing.Countries that had the most health policies regarding orphan drugs had 
a better rate of orphan drugs being accepted for reimbursement. conclusions: 
Though there are certain similarities across countries with regards to the HTA of 
orphan drugs, significant differences exist, which are likely to continue to cause 
variations in access to orphan drugs across countries. Positive listing by CADTH was 
one of the lowest between 5 countries and the economic recommendations were 
the most negative in Canada.Seperate funding for orphan drugs and specific clinical 
assessment should idealy be implemented throughout the world.
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oBjectives: Since the introduction of the European rare diseases policy in 2000, 82 
drugs have received orphan status. As the orphan drug market is rapidly expanding, 
this number is expected to increase. The research objective was to identify how 
European countries manage the increase in available orphan drugs and whether 
there are similarities or differences in orphan drug reimbursement policies across 
Europe. Methods: We assessed orphan drug policies in 16 European countries, 
grouped into four archetypes: health insurance markets (Austria, Belgium, France, 
Germany, The Netherlands, Switzerland); devolved markets (Italy, Spain); health eco-
nomic markets (Ireland, Portugal, UK); Nordic country markets (Denmark, Norway, 
Sweden). Policies were assessed considering five key factors: key stakeholders; 
treatment setting; evidence requirements; reimbursement processes; source of 
funding. results: In all country archetypes, except Nordic markets, the reimburse-
ment assessment of orphan drugs used for in- and out-patient care is the same. 
All archetypes, except health insurance markets, follow the same processes for 
orphan and non-orphan drugs. Although in Scotland and England, drugs classified 
as ultra-orphan go through specialised processes. In devolved markets, economic 
and clinical data are considered; in health insurance markets, economic data are 
only considered under certain circumstances in some countries. Nordic countries 
have fewer evidence requirements than other archetypes. In both health economic 
and health insurance markets, orphan drug funding varies with treatment setting. 
oBjectives: Anemia affects about 25% of the world population and is the second 
main cause of incapacity worldwide. Clinical guidelines recommend upfront use 
of iron (oral or intravenous, IV) to correct iron deficiency anemia (IDA) instead of 
blood transfusion (BT). Nonetheless, utilization of BT is a common practice fre-
quently associated with clinical complications and high economic burden. Our 
main objective was to estimate the impact of BT in hospital length of stay (LOS) 
and in intra- and extra-hospital mortality of patients with IDA. Methods: This 
was a non-interventional, retrospective, single-center study. A convenience sam-
ple composed of 196 IDA patients treated with IV iron during 2013 was analyzed. 
Data was retrieved from patients’ clinical and pharmacy records. Between-group 
comparisons were performed using non-parametric methods (Mann-Whitney-
Wilcoxon and Kruskal Wallis). Logistic regression models were estimated to assess 
the odds of intra-hospital mortality. Kaplan-Meier survival estimates and Peto test 
were used to assess survival after hospital discharge (extra-hospital mortality). A 
5% significance level was adopted. results: Here we present the results of the 
subset of 136 hospitalized patients, mean (SD) age of 68.6 (18.7) years and 50.7% 
males, corresponding to 148 hospitalization episodes. In 62.2% of these episodes 
at least 1BT was performed. Mean LOS was significantly higher in patients with 
BT (29.2 versus 15.3 days; p-value< 0.0001). The odds ratio of dying during hospi-
talization in patients with > 2BT was 3.73 (95%CI: 1.01-13.74) when compared to 
patients with ≤ 2BT, adjusting for age, sex, surgery or iron IV utilization. We observed 
a higher extra-hospital mortality in BT patients although not statistically significant 
(p-value= 0.118), probably due to the low number of patients with follow-up data 
(n= 33). conclusions: Blood transfusions result in higher hospital length of stay 
and mortality. A better patient blood-management may improve patient outcomes 
and provide a more efficient use of health resources.
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oBjectives: Current validated DAIs in SLE require disease expertise and/or 
involve complex scoring systems, and are often impractical for use in daily clini-
cal practice. To address this, several new simplified DAIs in SLE are in different 
stages of development, including SLE Activity Tracking Evaluation Tool (LAST:14 
items; includes medications, Physician Global Assessment (PhGA) 0-10 scale, Patient 
Global Assessment (PtGA:0-10), C3, C4 & anti-dsDNA lab measures), Clinical LAST 
(C-LAST:11 items; similar to LAST, without lab measures), Total Lupus Activity Score 
(TLAS:30 items; includes 15 physician clinical assessments and 15 patient self-
assessment of symptoms), and Simple Disease Assessment for People with Lupus 
Erythematosus (SIMPLE:17 items; includes patient self-assessment of symptoms, 
Lupus Impact Tracker, steroid medication, C3, C4 & proteinuria). The primary objec-
tive of this analysis is to assess the convergent validity of these various tools as 
well as PhGA indices in relation to SLEDAI-2K. Methods: This is a prospective real-
world observational cohort study of SLE patients receiving standard care in 2 private 
and 2 academic sites in the US. Respective portions of DAIs are completed by physi-
cians and patients at four timepoints: baseline/3mo/6mo/12mo. DAI completions: 
SLEDAI-2K:201; TLAS/SIMPLE: approx. 152; LAST/C-LAST:168. Pearson correlation 
coefficient (r) was computed comparing mean SLEDAI-2K score to other DAI scores 
at baseline. results: 201 SLE patients were enrolled (mean age:45yrs; female:91%; 
Black/African-American (AA):56%; Hispanic:10%). At baseline, mean SLEDAI-2K score 
was 3.4 (SD:3.2); each of the DAIs had statistically significant positive correlation 
with the SLEDAI-2K: LAST (r= 0.566/p< 0.0001), PhGA:0-10 scale (r= 0.563/p< 0.0001), 
SIMPLE (r= 0.560/p< 0.0001), PhGA:0-3 scale (r= 0.553/p< 0.0001), C-LAST (r= 0.450/
p< 0.0001) and TLAS (r= 0.348/p< 0.0001). Analysis stratified by AA and non-AA sta-
tus revealed similarly significant correlations between SLEDAI-2K and the other 
DAIs. conclusions: In this cross-sectional analysis, each of the studied DAIs 
appeared to have convergent validity with the SLEDAI-2K. Further analyses with 
longitudinal data will assess additional psychometric properties of the instruments.
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oBjectives: Developing innovative treatments for rare diseases is intrinsically 
difficult due to small patient population sizes and the scarcity of high quality evi-
dence. Orphan drug designation is attributed to drugs which have been developed 
to treat rare diseases; however, the European Medicines Agency (EMA) and US Food 
and Drug Administration (FDA) define rare diseases differently. The objective of this 
study was therefore to investigate the number and type of orphan drug designations 
across the EMA and FDA. Methods: Data on authorised drugs awarded orphan 
status by the EMA and FDA is freely available and was obtained from their respec-
tive websites. Authorised orphan drugs were analysed dating back to the first EMA 
orphan drug designation in 2002. results: The EMA designated 82 drugs orphan 
status, whilst the FDA designated 170 drugs orphan status. An upward trend in 
the number of drugs designated orphan status by the EMA was observed, whilst 
a downward trend was present in FDA orphan designations. The distribution of 
orphan drugs across WHO Anatomical Therapeutic Chemical (ATC) classifications 
appears to vary, for instance: 18% of EMA authorised orphan drugs were in the 
alimentary tract and metabolism group (ATC code A), compared to just 6% of FDA 
orphan drugs. Conversely, orphan drugs in the blood and blood forming organs 
category (ATC code B) comprised 2% of EMA authorised orphan drugs compared 
to 12% with the FDA. conclusions: The EMA has designated half the number of 
drugs orphan status compared to the FDA however the number of authorised drugs 
designated orphan status appears to be on the rise in Europe. The pattern of orphan 
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development and special grant programs are available in the USA and Japan. Only in 
South Korea, products that have already obtained orphan designation in elsewhere 
can benefit from a partial exemption from dossier submission for orphan designa-
tion and market authorization. conclusions: OD regulation and incentives are 
similar by nature but differ in magnitude. It is unclear how the profitability criteria 
are applied in US as multiple orphan products are blockbuster. USA applies the 
mildest criteria for granting orphan status and provides the greatest financial sup-
port. The financial assistance is the most modest in the EU while exclusivity is the 
longest. EU adds an additional layer at member state level.
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oBjectives: In order to stimulate the research and development of orphan drugs, in 
2000 the EU introduced new legislation with the aim of providing incentives for the 
development of drugs for rare disorders. One of the strongest incentives, regarding 
experience in the United States of America and Japan, is a market exclusivity period 
post authorization for designated products. The objective of this study is to assess if 
the 10 year market exclusivity has created a market failure by assessing the prices 
and the competition environment of drugs for which this period has come to an 
end. Methods: From the 2014 Orphanet’s list, we retrieved the 20 drugs that have 
lost their market exclusivity for at least one indication (26 indications). It is worth to 
note that some of them still have market exclusivity for another indication, which 
means they may still be on the orphan drug register. We focused on the French mar-
ket and used French administrated prices. results: 63% (12 drugs) of the sample 
have not suffered a drop in prices after the market exclusivity loss. Among all the 
studied variables, the most important event to trigger a price drop seems to be an 
extension of indication. 40% (10 drugs) of the sample were able to see the arrival 
of competitors during their period of market exclusivity even if they target a small 
population. conclusions: These results show that the market exclusivity does 
not necessarily create an inflationary effect and a monopoly for orphan drugs. 
Market exclusivity would act as a protectionist measure. Its major interest is in the 
beginning of the product’s life and for old drugs for which the molecule is not under 
the patent at the time of the approval.
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oBjectives: The use of cost effectiveness analysis for treatments for rare diseases 
has proved difficult and alternative frameworks for assessing value and determin-
ing pricing and reimbursement have been sought. Here we summarise rare disease 
specific methodologies proposed in the literature. Methods: A systematic litera-
ture review of Medline and EMBASE databases was conducted for the period 2000 
– 2014 without geographic restriction. The search sought to identify papers that 
proposed specific frameworks for a) assessing the value of rare disease treatments 
or b) determining the price or reimbursement status of such drugs. Policy papers, 
commentaries, and review articles were included. Clinical or economic studies of 
specific rare diseases and their treatments were excluded. results: The litera-
ture review identified 1,034 papers. Eleven studies proposed specific methods for 
assessing rare disease treatments. The most commonly proposed approach (7 of 
11 papers) involved multi-criteria decision analysis. Of these studies, 5 proposed 
MCDA frameworks; one study applied and validated MCDA frameworks with rare 
disease stakeholders and another study investigated the relationship between 
MCDA domain attributes and the cost of rare disease drugs. Of non-MCDA meth-
ods, one study described a novel decision making framework that balances payer 
value factors with opportunity cost, and another discussed a policy framework for 
funding rare disease treatments in Ontario. Two studies specified non-value based 
pricing frameworks: one cost-based pricing and another ‘grant and access’ pricing. 
Limitations included challenges identifying representative societal preferences, 
determining the perspective from which value should be assessed, and resistance to 
transparency from decision makers. conclusions: The need for a new framework 
for the evaluation of rare disease treatments has been commonly recognised in the 
published literature. A number of authors have proposed alternative approaches to 
cost effectiveness, but practical challenges are limiting their application currently.
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oBjectives: The aim of this study was to review and compare decisions of par-
ticular European HTA Agencies as well as orphan drugs’ reimbursement status in 
corresponding countries. Methods: 93 orphan drugs, approved in Europe, were 
identified. We considered the following European HTA Agencies: AOTM (Poland), 
NICE (England), AWMSG (Wales), HAS (France), SMC (Scotland), IQWIG (Germany). 
Data on the Agencies’ recommendations (positive, negative, conditional) and reim-
bursement status were collected for each drug. results: Among all identified 
orphan drugs 18%-60% were assessed by the HTA Agencies in particular countries. 
AWMSG assessed 56 orphans, and IQWIG only 17 drugs. Among 93 orphan drugs 
23 (25%) have never been assessed by any of analyzed European HTA Agencies. 
The average rates of positive, negative and conditional recommendations among 
included Agencies were 51.6%, 39.4% and 9.0%, respectively. The highest rate of 
positive recommendations was obtained by HAS Agency (France) which was 89.4%, 
and the lowest by AOTM (Poland) - 17.9%, but AOTM has issued also 42.9% condi-
tional recommendations. On average, 13% of approved orphan drugs are reimbursed 
In contrast, there are strong differences in the reimbursement of orphan drugs in 
Nordic and devolved markets. Relevant stakeholders in reimbursement assessment 
are national HTA (health technology assessment) agencies or regional authorities. 
In all archetypes, except health insurance markets, regional authorities are the 
relevant funding stakeholders. conclusions: There are several similarities and 
differences in orphan drug reimbursement across European countries. While some 
countries do not differentiate between orphan and non-orphan drugs in decision-
making or funding, others have implemented specific policies.
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oBjectives: The present work reviews current practices for the definition of the reim-
bursed price of orphan drugs, and proposes a conceptual framework for their value-
based pricing along with a roadmap for its possible implementation. Methods: 
Based on a literature analysis, we systematize the current discussions on the topic 
within a conceptual framework intended to support evaluations and decision-making 
for determining a value-based reimbursed price for orphan drugs. results: Our anal-
ysis points out the “black box” pricing mechanism of orphan drugs and the limited 
consistency of some of the constituent domains of Health Technology Assessment 
when applied to orphan medical products (safety, clinical effectiveness, costs and 
economic evaluation, ethical analysis, and organizational and social aspects). The 
proposed framework comprises: a) elements of societal value and methods for its 
assessment, b) exchanges of valuable and trustworthy information between relevant 
stakeholders from an early stage, c) innovative reimbursement approaches to balance 
the need for evidence-based decisions with timely access to innovative drugs for 
patients with rare diseases, d) societal participation in the risky entrepreneurship of 
producing orphan drugs. Considering the areas reported in the proposed framework, 
we identified a possible roadmap for its implementation via three critical phases: i) 
sharing available experiences, ii) integrating and systematizing methods for appro-
priate use, iii) identifying delegate agencies. conclusions: Additional piloting of 
emerging experiences and sharing of implementations developed worldwide are 
needed, along with the identification of an internationally agreed-upon taxonomy 
and pan-national recognised subjects to be delegated part of the HTA activities cur-
rently spread over a multiplicity of subjects.
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oBjectives: In 2000 EU introduced an orphan legislation in order to stimulate 
the development of drugs for rare diseases. Nevertheless, the actual availability of 
orphan drugs (ODs) in the EU depends on national authorities. The study aims to 
compare OD availability and market access in France and the UK. Methods: The 
details on OD prices and reimbursement were extracted from Ameli database in 
France and British National Formulary in the UK. The molecules were considered 
available if the price were published. NICE recommendations were extracted from 
the official website. results: 55 and 56 ODs were available in the UK and France, 
respectively, among 82 ODs authorized in the EU. 50 ODs were available in the two 
countries. Most of ODs sold in pharmacy were 100% or 65% reimbursed in France. 
All drugs are 100% reimbursed in the UK and when used in hospital in France. 
Only 20 ODs were assessed by the NICE in 24 indications. In 10 cases NICE did not 
recommend the drug, in five cases the indication was restricted. For more than 
60% of molecules prices were higher in the UK. The median difference was about 
10%. conclusions: The number of commercialized ODs is similar in the two 
countries. However, given the fact that most of ODs has not been recommended by 
the NICE, it is unlikely that they will be prescribed. Prices are free of control in the 
UK leading to higher prices compared with France. Although prices are published 
in the both countries, the real prices are impacted by implementing patient access 
schemes in the UK and hidden volume agreements in France. Interestingly, while 
cost-effectiveness assessment is becoming mandatory in France, NICE introduces 
a new methodology for OD moving away from economic evaluation.
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oBjectives: The study aims to review and compare orphan drug (OD) policies in 
the USA, EU, Japan and South Korea. Methods: The OD policies (regulation and list 
of incentives) were extracted from the official websites of the regulatory authori-
ties. results: USA was the first to implemented OD legislation in 1983, followed 
by Japan (1993), South Korea (1997), and the EU (2000). The prevalence threshold 
is the highest in the USA and the lowest in Japan. The rarity of the disease or the 
lack of profitability is the only criteria for granting orphan status in the USA. In 
the EU, Japan and South Korea high unmet needs should be demonstrated. Some 
non-rare conditions are eligible for orphan designation in Japan and South Korea. 
Development feasibility needs to be proven in Japan. Specific scientific assistance 
is available in all regions except South Korea. Market exclusivity is granted for 
10 years in the EU and 7 years in the USA. Financial assistance through fees reduc-
tion is available in all geographies. All regions but the EU also provide fast track 
marketing authorization procedure. Tax credits and/or tax reduction for clinical 
